product summary
Loading...
company name :
R&D Systems
product type :
chemical
product name :
SB 328437
catalog :
3650/10
quantity :
10 mg
price :
253 USD
more info or order :
citations: 7
| Reference |
|---|
Abonyo B, Alexander M, Heiman A. Autoregulation of CCL26 synthesis and secretion in A549 cells: a possible mechanism by which alveolar epithelial cells modulate airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2005;289:L478-88 pubmed
|
product information
brand :
Tocris
master code :
3650
SKU :
3650/10
product name :
SB 328437
sizes available :
10 mg
target :
Chemokine Receptor Antagonists
category :
Small Molecules
purity :
98%
observed molecular weight :
378.38
url print :
?utm_source=biocompare&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules
details of functionality :
SB 328437 is a potent and selective CCR3 antagonist (IC50 = 4 nM). Displays 2500-fold selectivity over C5aR, LTD4, CCR7, CXCR1 and CXCR2 receptors. Inhibits eotaxin-, eotaxin-2- and MCP-4-induced Ca2+ mobilization (IC50 values are 38, 35 and 20 nM respectively) and inhibits eotaxin-, eotaxin-2- and MCP-4-induced eosinophil chemotaxis with similar potencies.
top caption :
Potent and selective CCR3 antagonist
extended description :
Potent and selective CCR3 antagonist
chemical name text :
N-(1-Naphthalenylcarbonyl)-4-nitro-L-phenylalanine methyl ester
formula :
C21H18N2O5
formula text :
C21H18N2O5
cas num :
247580-43-4
USD :
253 USD
product details :
Potent and selective CCR3 antagonist
storage :
Store at +4°C
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
browse more products
questions and comments
